PMID- 33209021
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 15
DP  - 2020
TI  - Clinical Characteristics and Outcomes of Patients with Asthma-COPD Overlap in 
      Japanese Patients with COPD.
PG  - 2923-2929
LID - 10.2147/COPD.S276314 [doi]
AB  - PURPOSE: Asthma-COPD overlap (ACO) has been reported as an association with a 
      lower quality of life, frequent exacerbations, and higher mortality than those 
      with COPD alone. However, clinical characteristics and outcomes of ACO remain 
      controversial. PATIENTS AND METHODS: We conducted a prospective observational 
      study analyzing data of patients with stable COPD enrolled from the Ishinomaki 
      COPD Network Registry. Patients with features of asthma who had a history of 
      respiratory symptoms that vary over time and intensity, together with documented 
      variable expiratory airflow limitation, were identified, and then defined as 
      having ACO. The characteristics, frequency of exacerbations, and mortality during 
      the 3-year follow-up were compared between patients with ACO and patients with 
      COPD alone. RESULTS: Among 387 patients with COPD, 41 (10.6%) were identified as 
      having ACO. Patients with ACO tended to be younger, have higher BMI, have a 
      shorter smoking history, and use more respiratory medications, especially inhaled 
      corticosteroids. Inflammatory biomarkers including fractional exhaled nitric 
      oxide, blood eosinophil count, total immunoglobulin E (IgE) level, and presence 
      of antigen-specific IgE were significantly higher in patients with ACO than in 
      those with COPD alone. Lung function, mMRC score, CAT score, and comorbidity 
      index were not different between the groups. The annual rate of all exacerbations 
      and severe exacerbations required hospital admission were not different between 
      ACO and COPD alone (0.20 vs 0.14, 0.12 vs 0.10, events per person, respectively). 
      Mortality was significantly higher in patients with COPD alone compared with 
      those with ACO during the study period (P=0.037). CONCLUSION: The results of our 
      study indicate that ACO is not associated with poor clinical features nor 
      outcomes in an outpatient COPD cohort receiving appropriate treatment.
CI  - (c) 2020 Kobayashi et al.
FAU - Kobayashi, Seiichi
AU  - Kobayashi S
AUID- ORCID: 0000-0003-1347-3395
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
FAU - Hanagama, Masakazu
AU  - Hanagama M
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
FAU - Ishida, Masatsugu
AU  - Ishida M
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
FAU - Ono, Manabu
AU  - Ono M
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
FAU - Sato, Hikari
AU  - Sato H
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
FAU - Yamanda, Shinsuke
AU  - Yamanda S
AUID- ORCID: 0000-0002-8771-844X
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
AD  - Department of Pulmonary Medicine, Sendai Kosei Hospital, Sendai, Miyagi, Japan.
FAU - Yanai, Masaru
AU  - Yanai M
AUID- ORCID: 0000-0002-6181-7992
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Miyagi, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201112
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
SB  - IM
MH  - *Asthma/diagnosis/drug therapy/epidemiology
MH  - Eosinophils
MH  - Humans
MH  - Japan/epidemiology
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
MH  - Quality of Life
PMC - PMC7669510
OTO - NOTNLM
OT  - COPD
OT  - asthma
OT  - asthma-COPD overlap
OT  - exacerbations
OT  - mortality
COIS- Dr Seiichi Kobayashi reports personal fees from Boehringer Ingelheim, 
      Bristol-Myers Squibb, TEIJIN PHARMA LIMITED., and Kyowa Kirin Co., Ltd., grants 
      from GlaxoSmithKline, and grants and personal fees from AstraZeneca and Novartis, 
      outside the submitted work. The authors report no other potential conflicts of 
      interest in this work.
EDAT- 2020/11/20 06:00
MHDA- 2021/06/29 06:00
PMCR- 2020/11/12
CRDT- 2020/11/19 05:41
PHST- 2020/08/15 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/19 05:41 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/11/12 00:00 [pmc-release]
AID - 276314 [pii]
AID - 10.2147/COPD.S276314 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2020 Nov 12;15:2923-2929. doi: 
      10.2147/COPD.S276314. eCollection 2020.